[go: up one dir, main page]

PE20070367A1 - Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa - Google Patents

Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa

Info

Publication number
PE20070367A1
PE20070367A1 PE2006000854A PE2006000854A PE20070367A1 PE 20070367 A1 PE20070367 A1 PE 20070367A1 PE 2006000854 A PE2006000854 A PE 2006000854A PE 2006000854 A PE2006000854 A PE 2006000854A PE 20070367 A1 PE20070367 A1 PE 20070367A1
Authority
PE
Peru
Prior art keywords
inhibitors
compounds
secretase enzyme
beta secretase
triazaespiro
Prior art date
Application number
PE2006000854A
Other languages
English (en)
Inventor
Craig A Coburn
Samuel L Graham
Shaun R Stauffer
Wanli Lu
Bruce Fahr
Wenjin Yang
Georgia B Mcgaughey
Melissa S Egbertson
Original Assignee
Merck & Co Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Sunesis Pharmaceuticals Inc filed Critical Merck & Co Inc
Publication of PE20070367A1 publication Critical patent/PE20070367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) O SU TAUTOMERO DE FORMULA (I') DONDE R1 ES H, ALQUILO(C1-C10), CICLOALQUILO(C3-C12), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON H, HALO, OH, ENTRE OTROS; R2 ES HALO, CN, ALQUILO(C1-C10), ENTRE OTROS; R3 ES H, ALQUILO(C1-C10), FENILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON HALO, OH, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5(R,S),7(R,S)-8-BENCIL-4-(CICLOHEXILAMINO)-1-(3-FLUOROFENIL)-7-METIL-1,3,8-TRIAZAESPIRO[4,5]DEC-3-EN-2-ONA RACEMICA (DIASTEREOMERO A), 5(R,S),7(S,R)-8-BENCIL-4-(CICLOHEXILAMINO)-1-(3-FLUOROFENIL)-7-METIL-1,3,8-TRIAZAESPIRO[4,5]DEC-3-EN-2-ONA RACEMICA (DIASTEREOMERO B), 5(R,S),7(R,S)-4-(CICLOHEXILAMINO)-1-(3-FLUOROFENIL)-8-(3-ISOPROPOXIBENCIL)-7-METIL-1,3,8-TRIAZAESPIRO[4,5]DEC-3-EN-2-ONA RACEMICA (DIASTEREOMERO A), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA BETA SECRETASA SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2006000854A 2005-07-18 2006-07-17 Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa PE20070367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70009005P 2005-07-18 2005-07-18

Publications (1)

Publication Number Publication Date
PE20070367A1 true PE20070367A1 (es) 2007-05-12

Family

ID=37491690

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000854A PE20070367A1 (es) 2005-07-18 2006-07-17 Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa

Country Status (12)

Country Link
US (1) US8211904B2 (es)
EP (1) EP1910364B1 (es)
JP (1) JP2009502786A (es)
CN (1) CN101238124A (es)
AR (1) AR054560A1 (es)
AT (1) ATE550338T1 (es)
AU (1) AU2006270084B2 (es)
CA (1) CA2615656A1 (es)
DO (1) DOP2006000169A (es)
PE (1) PE20070367A1 (es)
TW (1) TW200728305A (es)
WO (2) WO2007011833A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
RU2390350C2 (ru) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Активная иммунизация для создания антител к растворимому а-бета
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008523815A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
US20100298342A1 (en) * 2006-09-07 2010-11-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
JP2010505833A (ja) * 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのマクロ環式スピロピペリジンβ−セクレターゼ阻害剤
CA2668065A1 (en) * 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US8377954B2 (en) * 2007-01-04 2013-02-19 Merck, Sharp & Dohme, Corp Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PT2233474E (pt) 2008-01-18 2015-10-26 Eisai R&D Man Co Ltd Derivado de aminodihidrotiazina condensado
CA2721786A1 (en) * 2008-05-05 2009-11-12 Pfizer Inc. Novel class of spiro piperidines for the treatment of neurodegenerative diseases
ES2433223T3 (es) * 2008-07-28 2013-12-10 Eisai R&D Management Co., Ltd. Derivados de espiroaminodihidrotiazina
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
BRPI0918449A2 (pt) 2008-09-11 2019-09-24 Amgen Inc compostos de anel espiro-tricíclico como moduladores de beta-secretas e métodos de uso
US8198269B2 (en) 2008-09-30 2012-06-12 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2370439A1 (en) * 2008-11-23 2011-10-05 Pfizer Inc. Lactams as beta secretase inhibitors
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011115928A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use
CA2791281A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
EP2556076A2 (en) 2010-04-09 2013-02-13 Pfizer Inc. Novel sultam compounds
WO2012019056A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
US8957083B2 (en) 2010-11-23 2015-02-17 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
BR112013016241A2 (pt) 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2821401B1 (en) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016139501A1 (en) * 2015-03-04 2016-09-09 Tfchem Gem difluorocompounds as depigmenting or lightening agents
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP4069708A4 (en) * 2019-12-03 2024-03-20 Kallyope, Inc. Sstr5 antagonists
CN117143004A (zh) * 2023-08-30 2023-12-01 安徽农业大学 一种手性氮杂螺环类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710504A (en) 1986-04-04 1987-12-01 Merck & Co., Inc. Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
CZ36394A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20040067950A1 (en) 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1461339B1 (en) 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
NZ560368A (en) 2002-05-03 2008-11-28 Israel Inst Biolog Res Methods and compostions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
EP1515944A1 (en) 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
JP2006512404A (ja) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
US20060116366A1 (en) 2002-12-04 2006-06-01 Parmee Emma R Spirocyclic ureas, compositions containing such compounds and methods of use
AU2003296992A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
CA2529739A1 (en) 2003-06-16 2005-01-20 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
AU2005295814A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease

Also Published As

Publication number Publication date
WO2007011833A3 (en) 2007-03-29
WO2007011810A1 (en) 2007-01-25
EP1910364A2 (en) 2008-04-16
JP2009502786A (ja) 2009-01-29
DOP2006000169A (es) 2007-02-28
AU2006270084A1 (en) 2007-01-25
CA2615656A1 (en) 2007-01-25
US8211904B2 (en) 2012-07-03
TW200728305A (en) 2007-08-01
CN101238124A (zh) 2008-08-06
US20070021454A1 (en) 2007-01-25
AR054560A1 (es) 2007-06-27
ATE550338T1 (de) 2012-04-15
AU2006270084B2 (en) 2011-08-25
EP1910364B1 (en) 2012-03-21
WO2007011833A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
TW200505919A (en) DPP-IV inhibitors
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
GEP20146046B (en) Organic compounds
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
TN2011000053A1 (en) Organic compounds
PE20091095A1 (es) Moduladores de gamma secretasa
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
GB0305152D0 (en) Organic compounds
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
MA32903B1 (fr) Inhibiteurs de proteine-kinases
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
MX2007013624A (es) Inhibidores de proteina cinasa.
PE20091649A1 (es) Derivados de pirrolidinilo

Legal Events

Date Code Title Description
FC Refusal